Wegovy
Pila Pharma raises SEK 20m to advance new oral obesity treatment
July 8, 2025Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
Veru announces first patients enrolled in phase 2b trial for weight loss treatment
May 1, 2024Research and Development Obesity, Veru, Wegovy, enobosarm, weight loss
Veru has announced that it has enrolled the first patients into its phase 2b clinical trial of enobosarm, an oral …
Novo Nordisk launches Wegovy in the UK
September 4, 2023Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …
Novo Nordisk’s Wegovy reduces risk of cardiovascular events
August 9, 2023Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …
UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity
June 7, 2023Research and Development NHS, Novo Nordisk, Obesity, Wegovy, clinical trial, obesity
The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …
